The association between metabolic syndrome and prostate-specific antigen levels

International Journal of Urology

Volumn 15, Issue 10, 2008, Pages 905-909

  Kim, Yong June ^a   Cho, Yong Jin ^b   Oh, Jung Eun ^b   Jeon, Youn Soo ^b   Lee, Sang Cheol ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

Glucose intolerance; Metabolic syndrome; Obesity; Prostate specific antigen; Screening

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CANCER DIAGNOSIS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE BIOPSY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN;

EID: 54049111839     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02137.x     Document Type: Article

References (34)

1. Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: Lower values than for similarly aged white men. Br. J. Urol. 1995 75 : 347 53.
2. Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 2005 66 : 108 13.
3. Baillargeon J, Pollock BH, Kristal AR et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005 103 : 1092 5.
4. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006 106 : 320 8.
5. Freedland SJ, Platz EA, Presti JC Jr. et al. Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection. J. Urol. 2006 175 : 500 4.
6. Kim YJ, Han BK, Hong SK, Byun SS, Kim WJ, Lee SE. Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int. J. Urol. 2007 14 : 1009 12.
7. Fowke JH, Matthews CM, Buchowski MS et al. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2007 in press).
8. Chun FK, Hutterer GC, Perrotte P et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int. 2007 100 : 37 41.
9. Kobayashi T, Kinoshita H, Nishizawa K, Mitsumori K, Ogawa O, Kamoto T. Age-associated increase of prostate-specific antigen in a high level of men visiting urological clinics. Int. J. Urol. 2005 12 : 733 8.
10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988 37 : 1595 607.
11. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 2002 156 : 1070 7.
12. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004 110 : 1245 50.
13. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J. Natl. Cancer Inst. 2004 96 : 1152 60.
14. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol. Biomarkers Prev. 2002 11 : 385 91.
15. Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J. Natl. Cancer Inst. 2002 94 : 1293 300.
16. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: Another aspect of the insulin-resistance syndrome? Obes. Rev. 2002 3 : 303 8.
17. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 2007 51 : 199 206.
18. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 2001 39 : 151 8.
19. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998 1 : 157 62.
20. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004 13 : 47 55.
21. Hammarsten J, Hogstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur. J. Cancer 2005 41 : 2887 95.
22. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol. Biomarkers Prev. 2004 13 : 1646 50.
23. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am. J. Epidemiol. 2006 164 : 769 74.
24. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
25. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005 366 : 1059 62.
26. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 1996 312 : 1079.
27. World Health Organization. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004 363 : 157 63.
28. Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology 2002 59 : 41 50.
29. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes Control 2006 17 : 989 1003.
30. Hsing AW, Chua S Jr., Gao YT et al. Prostate cancer risk and serum levels of insulin and leptin: A population-based study. J. Natl. Cancer Inst. 2001 93 : 783 9.
31. Hsing AW, Deng J, Sesterhenn IA et al. Body size and prostate cancer: A population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev. 2000 9 : 1335 41.
32. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003 108 : 1541 5.
33. Ku JH, Ahn JO, Lee CH et al. Distribution of serum prostate-specific antigen in healthy Korean men: Influence of ethnicity. Urology 2002 60 : 475 9.
34. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 2004 350 : 2239 46.